Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation

Author
D. Nordell, Anna, McKenna, Matthew, H. Borges, Alvaro, Duprez, Daniel, Neuhaus, Jacqueline, D. Neaton, James, Rogers, Gary, Group, SMART Study, Groups, ESPRIT Study, Committee, SILCAAT Scientific

Published
2014

Journal Title
Journal of American Heart Association

DOI
https://doi.org/10.1161/JAHA.114.000844

Copyright Statement
Copyright 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Downloaded from
http://hdl.handle.net/10072/68843
Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation

Anna D. Nordell, BA; Matthew McKenna, BA; Álvaro H. Borges, MD, MSc; Daniel Duprez, MD, PhD; Jacqueline Neuhaus, MS; James D. Neaton, PhD; for the INSIGHT SMART, ESPRIT Study Groups, and SILCAAT Scientific Committee*

Background—In the general population, raised levels of inflammatory markers are stronger predictors of fatal than nonfatal cardiovascular disease (CVD) events. People with HIV have elevated levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer; HIV-induced activation of inflammatory and coagulation pathways may be responsible for their greater risk of CVD. Whether the enhanced inflammation and coagulation associated with HIV is associated with more fatal CVD events has not been investigated.

Methods and Results—Biomarkers were measured at baseline for 9764 patients with HIV and no history of CVD. Of these patients, we focus on the 288 that experienced either a fatal (n=74) or nonfatal (n=214) CVD event over a median of 5 years. Odds ratios (ORs) (fatal versus nonfatal CVD) (95% confidence intervals [CIs]) associated with a doubling of IL-6, D-dimer, hsCRP, and a 1-unit increase in an IL-6 and D-dimer score, measured a median of 2.6 years before the event, were 1.39 (1.07 to 1.79), 1.40 (1.10 to 1.78), 1.09 (0.93 to 1.28), and 1.51 (1.15 to 1.97), respectively. Of the 214 patients with nonfatal CVD, 23 died during follow-up. Hazard ratios (95% CI) for all-cause mortality were 1.72 (1.28 to 2.31), 1.73 (1.27 to 2.36), 1.44 (1.15 to 1.80), and 1.88 (1.39 to 2.55), respectively, for IL-6, D-dimer, hsCRP, and the IL-6 and D-dimer score.

Conclusions—Higher IL-6 and D-dimer levels reflecting enhanced inflammation and coagulation associated with HIV are associated with a greater risk of fatal CVD and a greater risk of death after a nonfatal CVD event.


Key Words: cardiovascular disease • inflammation

Over 15 years ago, an association between enhanced inflammation, as demonstrated by higher plasma levels of C-reactive protein (CRP), and risk of coronary heart disease (CHD) in middle-aged men without previous cardiovascular disease (CVD) was reported using data from the Multiple Risk Factor Intervention Trial (MRFIT). In MRFIT, CRP was strongly related to CHD mortality, but was not related to nonfatal myocardial infarction (MI). Importantly, most of the CHD deaths occurred more than 10 years after the CRP measurement. This MRFIT observation that markers of inflammation are stronger predictors of fatal, as compared to nonfatal, CHD events has been confirmed in other studies. Reasons for this finding include the possibility that patients with higher inflammatory markers may have different underlying vascular disease. It has been speculated that patients with greater levels of inflammation might be more likely to experience fatal arrhythmias that result in sudden death or have greater levels of inflammation in unstable plaques. It is also possible that low-grade inflammation results in activation of the coagulation system, increasing the likelihood of fatal outcomes subsequent to plaque rupture. Other reasons include a greater presence of other CVD risk factors among those with higher inflammatory biomarker levels that increased risk of death, or the presence of other nonvascular conditions that are associated with chronic inflammation and that lead to an increased risk of fatal events.
Patients with HIV may contribute to our understanding of these findings in the general population. They are in a sustained inflammatory state even when taking suppressive antiretroviral therapy (ART). Reasons for this inflammatory state and the associated chronic state of immune activation have been reviewed. Some key findings concerning HIV, inflammation, and CVD, which we and others have described, are: (1) compared to age- and gender-matched people in the general population interleukin-6 (IL-6), high-sensitivity CRP (hsCRP), and D-dimer are elevated; (2) patients with HIV appear to be at an increased risk of CVD, compared to individuals without HIV; and (3) IL-6, hsCRP, and D-dimer measured several years beforehand are associated with all-cause mortality and fatal or nonfatal CVD. The results in the reports by Kuller and Duprez, which utilized stored plasma specimens from the Strategies for Management of Antiretroviral Therapy (SMART) trial, also suggested that though the associations of these biomarkers with fatal or non-fatal CVD was similar to associations reported in general population studies, the association with all-cause mortality was stronger than for CVD, even though the deaths in SMART were attributed to a number of different causes.

Collectively, these findings led us to formulate 2 hypotheses: (1) HIV-positive patients with higher levels of IL-6, hsCRP, and D-dimer, measured several years before the CVD event, are more likely to experience a fatal, as compared to a nonfatal, CVD event; and (2) mortality after nonfatal CVD events is higher among HIV-positive patients with higher, as compared to lower, levels of IL-6, hsCRP, and D-dimer, also measured several years before the nonfatal event. To investigate these hypotheses, we used data from SMART and 2 other large international clinical trials of HIV treatments.

**Methods**

**Study Populations**

This investigation included patients from 3 large international HIV treatment trials conducted by the International Network for Strategic Initiatives in Global HIV Trials, the SMART trial, the Evaluation of Subcutaneous Proleukin® in a Randomized International Trial (ESPRIT), and the Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active Antiretroviral Therapy (SILCAAT) trial. These trials were carried out in 33, 25, and 11 countries, respectively. The SMART study compared continuous ART with intermittent ART among HIV-positive patients with a CD4+ cell count of more than 350 cells/mm³. ESPRIT and SILCAAT compared IL-2 plus ART versus ART alone among HIV-positive patients with CD4+ counts of 300 cells/mm³ or more and with CD4+ counts of 50 to 299 cells/mm³, respectively. All studies were approved by an institutional review committee and patients were included only after giving informed consent.

**Biomarker Measurements**

IL-6, hsCRP, and D-dimer were measured at baseline, before randomization, in each trial using stored plasma for patients who provided written consent. For patients in SMART, these biomarkers were measured at the Laboratory for Clinical Biochemistry Research at the University of Vermont (Burlington). In the ESPRIT and SILCAAT trials, laboratory measurements were performed by SAIC-Frederick (Frederick, MD). All samples in both laboratories were analyzed blinded to treatment group and CVD event status. IL-6 was measured by the same method at each laboratory (Chemiluminescent Sandwich ELISA; R&D Systems, Minneapolis, MN). D-dimer levels were measured by ELISA on the Sta-R analyzer, Liatest D-Di (Diagnostic Stago, Parsippany, NJ), for patients in SMART and on a VIDAS instrument (bioMérieux Inc, Durham, NC) for patients in ESPRIT and SILCAAT. hsCRP was measured by ELISA by both laboratories. For SMART, a NBTMII nephelometer, N Antiserum to Human CRP (Siemens Diagnostics, Deerfield, IL), was used. For ESPRIT and SILCAAT, an R&D Systems ELISA assay was used. Twenty samples were independently analyzed at each laboratory for these biomarker levels. Table S1 summarizes the measurements made at each laboratory. Lower limits of detection (LLOD) for IL-6, hsCRP, and D-dimer were 0.16 pg/mL, 0.16 μg/mL, and 0.01 μg/mL for SMART. In ESPRIT and SILCAAT, LLOD were 0.156 pg/mL, 0.078 μg/mL, and 0.045 μg/mL.

**Baseline and Follow-up Measurements**

In all 3 studies, the following baseline measurements were obtained before randomization: age, sex, race, body mass index (BMI), CD4+ cell count, HIV-RNA, duration of ART, and previous AIDS clinical event. In SMART and ESPRIT, additional baseline measurements were made, including hepatitis B/C coinfection, diabetes, and use of blood pressure and lipid-lowering medication. For patients in SMART, smoking status was assessed and blood lipids were measured. During follow-up, HIV RNA levels and CD4+ cell counts were recorded every 4 months in each study.

**Events**

CVD events considered were deaths attributed to CVD, unwitnessed deaths that were not attributed to suicide, drug abuse, or violence, nonfatal MI, nonfatal stroke, and coronary artery disease (CAD) requiring surgery. In SMART and ESPRIT, documentation of CVD events that was provided by the
clinical sites were reviewed by an endpoint review committee using prespecified criteria.\(^1\) Criteria for acute MI followed the universal definition of MI.\(^1\) CAD requiring surgery required a procedure report, hospital discharge summary, or other medical record from the hospitalization during which the procedure was performed (coronary artery bypass graft, coronary artery stent implant, coronary artherectomy, or percutaneous transluminal angioplasty). For strokes, 5 criteria were considered: (1) acute onset with clinically compatible course, including unequivocal objective findings of a localizing neurological deficit; (2) computed tomography (CT) or magnetic resonance imaging (MRI) compatible with diagnosis of stroke and current neurologic signs and symptoms; (3) stroke diagnosed as cause of death at autopsy; (4) positive lumbar puncture compatible with subarachnoid hemorrhage; and (5) death certificate or death note from medical record listing stroke as the cause of death. A participant was considered to have experienced a stroke if the first and second criteria were met, the third criterion was met, the first and fourth criteria were met, or the first and fifth criteria were met. In SILCAAT, CVD events reported as serious adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedRA; version 12.0). The following Standardized MedRA Query codes were used for nonfatal stroke (20000082), nonfatal MI (20000047), and CAD requiring surgery (10068176, 10052086, 10057787, or 10063025). In all 3 studies, cause of death was coded using documentation of the death provided by the clinical sites using the Coding of Death in HIV system.\(^2\)

In addressing our first hypothesis, we defined fatal CVD events as: (1) deaths attributable to CVD or un witnessed deaths for patients that did not experience a nonfatal MI or stroke before their death and (2) deaths within 28 days after a nonfatal MI, stroke, or CAD. Patients who experienced MI, stroke, or CAD events and survived at least 28 days were defined as having nonfatal CVD events.

For our second hypothesis, we considered any patient with an MI, stroke, or CAD event who survived at least 28 days. For this group of patients, we assessed subsequent risk of all-cause mortality.

Statistical Analyses
Logistic regression, including indicators for study the patient was enrolled in (SMART, ESPRIT, SILCAAT), was used to study the association of each biomarker with fatal CVD. In addition to considering each biomarker individually, we also considered a combined IL-6 and D-dimer score used for predicting all-cause mortality among HIV patients with a suppressed viral load. Because of their independent association with all-cause mortality, the IL-6 and D-dimer score was created in order to account for the contribution of both markers in a single combined measure. This score was determined using the control arms of SMART, ESPRIT, and SILCAAT (144 deaths) and was adjusted for age, gender, and study; IL-6 and D-dimer were log\(_2\) transformed. The regression coefficients from this Cox model for IL-6 and D-dimer were then used to create the IL-6 and D-dimer score.\(^2,3\)

In this investigation, the biomarkers were log\(_2\) transformed because their distributions were right-skewed. With this approach, a 1 log\(_2\) higher level of a biomarker corresponds to a doubling of the marker. Results are also cited for tertiles of each biomarker, which were defined using all of the patients in the 3 studies that experienced a fatal or nonfatal CVD event. Other covariates, measured in each study, that were considered potential confounding factors were: time between biomarker measurement and the event, age, gender, race, baseline BMI, HIV RNA level, baseline CD4\(^+\) cell count, and earlier AIDS event at study entry. We also considered the interaction between time between biomarker measurement and the event with the log-transformed biomarker. In sensitivity analyses, we adjusted for hepatitis B/C coinfection, diabetes, and use of blood pressure and lipid-lowering medication (SMART and ESPRIT) and then added smoking and the ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol (SMART only). We also carried out separate analyses for patients in the control arms of the 3 studies. These patients were to receive continuous ART with a goal of suppressing HIV-RNA levels during follow-up. This is the recommended standard of care for patients with HIV.\(^2,3\)

Cumulative mortality after a nonfatal CVD event was estimated using the Kaplan-Meier method. Cox models that included study indicators were used to study factors related to mortality for the 214 patients who experienced a nonfatal CVD event. Models included the same covariates as the logistic model, as well as CD4\(^+\) cell counts and HIV-RNA levels both proximal to the nonfatal event. Hazard ratios (HRs) and 95% confidence intervals (CIs) are cited. The proportional hazards assumption was tested by including an interaction term between each biomarker and log-transformed follow-up time.

All analyses were performed using SAS statistical software (version 9.2; SAS Institute Inc., Cary, NC). \(P<0.05\) was considered significant.

Results
Among the 11 278 patients randomized in these trials (5472 SMART, 4111 ESPRIT, and 1695 SILCAAT), 10 001 (89%) had IL-6, hsCRP, and D-dimer measured on stored baseline plasma samples for consenting patients (5017 SMART, 3570 ESPRIT, and 1414 SILCAAT). Of these, 9764 (98%) did not report a history of CVD at study entry (Figure). Over a median (interquartile range; IQR) follow-up of 5.0 (2.3, 7.1) years, 74
of these 9764 patients developed fatal CVD; for 68 of these patients, the CVD event reported was death (36 resulting from CVD and 32 unwitnessed deaths); for 6 additional patients, death occurred within 28 days of a nonfatal CVD event (3 after a stroke and 3 after an MI). Two hundred and fourteen patients experienced an MI, stroke, or CAD event and survived at least 28 days (102 MIs, 43 strokes, and 69 CADs requiring surgery). Thus, 26% of CVD events (74 of 288) were fatal. The median (IQR) time from biomarker measurement at baseline to the event was 2.6 (1.1, 4.7) for fatal and non-fatal CVD events.

Comparison of Fatal and Nonfatal CVD Events

Baseline characteristics for patients according to the development of a CVD event during follow-up and its severity are summarized in Table 1. In these univariate analyses, IL-6, D-dimer, and the IL-6 and D-dimer score were significantly greater for those patients who experienced a fatal, as compared to a nonfatal, CVD event; hsCRP levels were also higher for those with fatal events, as compared to nonfatal events, but the difference was not significant ($P=0.26$). Consistent with a previous report, $^{13}$ levels of all 3 of the biomarkers were higher for patients who developed CVD, as compared to those who did not. Difference in biomarker levels for those with and without a CVD event, and by the severity of the CVD event, was consistent across all 3 studies (Table 2). In regression models, we considered the interaction of study with each biomarker and none were significant ($P>0.40$ for all). In the summary below, we pool the results for the 3 studies.

When considered as continuous log$_2$-transformed measurements, higher levels of IL-6, D-dimer, and the IL-6 and D-dimer score were associated with greater odds of a fatal CVD event (Table 3). This was evident in univariate and multivariate analyses. When tertiles were considered, significant differences between the third and first tertiles were found for IL-6, D-dimer, and the IL-6 and D-dimer score. The risk gradient, as judged by the odds ratio (OR) for a doubling of the biomarker and based on the tertile analysis, tended to be strongest for D-dimer and the IL-6 and D-dimer score and weakest for hsCRP. Interactions of each biomarker and time between

Figure. Flow diagram of patients included in analyses. CVD indicates cardiovascular disease; ESPRIT, Evaluation of Subcutaneous Proleukin® in a Randomized International Trial; SILCAAT, Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4$^+$ Counts under Active Antiretroviral Therapy; SMART, Strategies for Management of Antiretroviral Therapy.
biomarker measurement and the event were also considered and none were significant. Sensitivity analyses were performed, excluding the unwitnessed deaths, and results were similar to those in Table 3. For example, univariate ORs (95% CI) associated with a doubling of IL-6, D-dimer, hsCRP, and the IL-6 and D-dimer score were 1.41 (1.03 to 1.92), 1.36 (1.01 to 1.82), 1.13 (0.92 to 1.37), and 1.50 (1.08 to 2.07), respectively.

Considering the 206 patients (54 fatal and 152 nonfatal events) in SMART and ESPRIT that had measurements recorded at baseline, we adjusted for 4 additional covariates: diabetes, hepatitis B/C coinfection, and use of blood pressure and lipid-lowering medication. Adjusted ORs were similar to those shown in Table 3: for IL-6, D-dimer, hsCRP, and IL and D-dimer score, ORs (95% CIs) were 1.33 (95% CI, 0.95 to 1.86), 1.43 (95% CI, 1.02 to 2.00), 1.18 (95% CI, 0.95 to 1.47), and 1.49 (95% CI, 1.03 to 2.15), respectively.

For the 115 patients (31 fatal and 84 nonfatal events) in SMART for whom we could also adjust for smoking and total/HDL cholesterol, adjusted ORs were 1.10 (95% CI, 0.72 to 1.67), 1.39 (95% CI, 0.90 to 2.15), 1.25 (95% CI, 0.91 to 1.70), and 1.22 (95% CI, 0.78 to 1.93) for IL-6, D-dimer, hsCRP, and the IL-6 and D-dimer score, respectively.

In SMART, the OR associated with a doubling of IL-6 was lower than in analyses based on all 3 studies or based on SMART and ESPRIT. For all 5017 patients in SMART, median

Table 1. Baseline Characteristics for HIV-Positive Patients Who Experienced CVD Events According to Severity

<table>
<thead>
<tr>
<th>Baseline characteristics, n</th>
<th>No Event*</th>
<th>Fatal CVD†</th>
<th>Nonfatal CVD‡</th>
<th>P Value§</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), median (IQR)</td>
<td>42 (36 to 48)</td>
<td>48 (41 to 54)</td>
<td>49 (42 to 54)</td>
<td>0.76</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>22</td>
<td>14</td>
<td>8</td>
<td>0.21</td>
</tr>
<tr>
<td>Race (% black)</td>
<td>19</td>
<td>23</td>
<td>16</td>
<td>0.20</td>
</tr>
<tr>
<td>BMI (kg/m²), median (IQR)</td>
<td>24.3 (22.1 to 27.0)</td>
<td>24.0 (22.1 to 27.0)</td>
<td>24.3 (22.1 to 27.1)</td>
<td>0.58</td>
</tr>
<tr>
<td>CD4* cell count, (cells/mm³) median (IQR)</td>
<td>487 (367 to 669)</td>
<td>409 (331 to 644)</td>
<td>469 (356 to 633)</td>
<td>0.63</td>
</tr>
<tr>
<td>HIV-RNA&lt;500 copies/mL, %</td>
<td>77</td>
<td>74</td>
<td>77</td>
<td>0.64</td>
</tr>
<tr>
<td>Earlier AIDS event, %</td>
<td>26</td>
<td>39</td>
<td>29</td>
<td>0.10</td>
</tr>
<tr>
<td>IL-6, (pg/mL) median (IQR)</td>
<td>1.8 (1.2 to 2.8)</td>
<td>3.1 (1.9 to 4.5)</td>
<td>2.3 (1.5 to 3.5)</td>
<td>0.01↑</td>
</tr>
<tr>
<td>% highest tertile (&lt;1.88)</td>
<td>20</td>
<td>45</td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>% middle tertile (1.88 ≤ x &lt;3.14)</td>
<td>27</td>
<td>31</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>% lowest tertile (≥3.14)</td>
<td>52</td>
<td>24</td>
<td>36</td>
<td>0.02↑</td>
</tr>
<tr>
<td>D-dimer, (µg/mL) median (IQR)</td>
<td>0.24 (0.15 to 0.37)</td>
<td>0.35 (0.24 to 0.61)</td>
<td>0.27 (0.17 to 0.45)</td>
<td>0.006↓</td>
</tr>
<tr>
<td>% highest tertile (&lt;0.22)</td>
<td>21</td>
<td>45</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>% middle tertile (0.22 ≤ x &lt; 0.41)</td>
<td>31</td>
<td>32</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>% lowest tertile (≥0.41)</td>
<td>47</td>
<td>23</td>
<td>37</td>
<td>0.03↑</td>
</tr>
<tr>
<td>hsCRP, (µg/mL) median (IQR)</td>
<td>1.6 (0.7 to 3.6)</td>
<td>3.1 (1.1 to 7.5)</td>
<td>2.2 (1.1 to 5.6)</td>
<td>0.26↓</td>
</tr>
<tr>
<td>% highest tertile (&lt;1.55)</td>
<td>21</td>
<td>39</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>% middle tertile (1.55 ≤ x &lt;4.17)</td>
<td>29</td>
<td>32</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>% lowest tertile (≥4.17)</td>
<td>50</td>
<td>28</td>
<td>35</td>
<td>0.49↑</td>
</tr>
<tr>
<td>IL-6 and D-dimer score median (IQR)</td>
<td>–0.02 (–0.60 to 0.61)</td>
<td>0.85 (0.20 to 1.36)</td>
<td>0.30 (–0.20 to 0.89)</td>
<td>0.003</td>
</tr>
<tr>
<td>% highest tertile (&lt;1.04)</td>
<td>19</td>
<td>51</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>% middle tertile (1.04 ≤ x &lt;1.75)</td>
<td>28</td>
<td>26</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>% lowest tertile (≥1.75)</td>
<td>53</td>
<td>23</td>
<td>37</td>
<td>0.001↑</td>
</tr>
</tbody>
</table>

BMI indicates body mass index; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range.
*No event measurements noted for completeness.
†Deaths attributed to CVD and unwitnessed deaths not resulting from violence, suicide, or drug abuse that were not proceeded by a nonfatal event or deaths within 28 days of the nonfatal CVD event.
‡Nonfatal myocardial infarction, coronary artery disease requiring surgery, or nonfatal stroke for participants that survived at least 28 days.
§From a univariate logistic model comparing fatal and nonfatal CVD events (n=288).
||P values reported based on log₂-transformed biomarker measurement.
¶P value based on 2 df chi-square test.
#Tertiles were defined using all of the patients in the 3 studies that experienced a fatal or nonfatal CVD event.

DOI: 10.1161/JAHA.114.000844

Journal of the American Heart Association

Downloaded from http://jaha.ahajournals.org/ at Griffith University on October 23, 2014
**Table 2.** Characteristics of SMART, ESPRIT, and SILCAAT Patients With and Without Fatal/Nonfatal CVD Events

<table>
<thead>
<tr>
<th></th>
<th>SMART</th>
<th>ESPRIT</th>
<th>SILCAAT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics, n</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No Event</td>
<td>4697</td>
<td>3418</td>
<td>1361</td>
</tr>
<tr>
<td>Fatal CVD</td>
<td>32</td>
<td>26</td>
<td>16</td>
</tr>
<tr>
<td>Nonfatal CVD</td>
<td>86</td>
<td>91</td>
<td>37</td>
</tr>
<tr>
<td><strong>Age (y), median (IQR)</strong></td>
<td>43 (37 to 50)</td>
<td>40 (35 to 46)</td>
<td>48 (41 to 54)</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>27</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Race (% black)</td>
<td>29</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>BMI, (kg/m²) median (IQR)</td>
<td>25.0 (22.5 to 28.1)</td>
<td>25.7 (21.9 to 25.9)</td>
<td>24.4 (23.1 to 25.8)</td>
</tr>
<tr>
<td>BP-lowering drug use, %</td>
<td>17</td>
<td>4</td>
<td>N/A</td>
</tr>
<tr>
<td>Lipid-lowering drug use, %</td>
<td>14</td>
<td>10</td>
<td>N/A</td>
</tr>
<tr>
<td>Hepatitis B or C coinfection, %</td>
<td>17</td>
<td>22</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>CD4⁺ cell count, (cells/mm³) median (IQR)</strong></td>
<td>598 (467 to 794)</td>
<td>583 (450 to 838)</td>
<td>399 (341 to 516)</td>
</tr>
<tr>
<td>ART, %</td>
<td>84</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Time since first ART, (y) median (IQR)</td>
<td>6 (4 to 8)</td>
<td>5 (2 to 6)</td>
<td>4 (2 to 8)</td>
</tr>
<tr>
<td>Baseline HIV-RNA &lt;500 copies/mL, %</td>
<td>72</td>
<td>69</td>
<td>81</td>
</tr>
<tr>
<td>Earlier AIDS event, %</td>
<td>24</td>
<td>27</td>
<td>58</td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>6</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Smoker, %</td>
<td>41</td>
<td>52</td>
<td>N/A</td>
</tr>
<tr>
<td>Total/HDL cholesterol, (mmol/L) median (IQR)</td>
<td>4.6 (3.6 to 5.9)</td>
<td>6.1 (4.2 to 8.1)</td>
<td>N/A</td>
</tr>
<tr>
<td>IL-6, (µg/mL) median (IQR)</td>
<td>1.7 (1.1 to 2.9)</td>
<td>2.6 (1.8 to 4.5)</td>
<td>2.2 (1.5 to 3.1)</td>
</tr>
<tr>
<td>D-dimer, (µg/mL) median (IQR)</td>
<td>0.20 (0.13 to 0.37)</td>
<td>0.26 (0.19 to 0.37)</td>
<td>0.28 (0.19 to 0.42)</td>
</tr>
<tr>
<td>hsCRP, (µg/mL) median (IQR)</td>
<td>1.7 (0.7 to 4.0)</td>
<td>2.6 (1.4 to 3.2)</td>
<td>1.7 (1.0 to 4.2)</td>
</tr>
<tr>
<td>IL-6 and D-dimer score, median (IQR)</td>
<td>−0.12 (−0.81 to 0.64)</td>
<td>0.51 (−0.08 to 1.14)</td>
<td>0.56 (0.29 to 0.92)</td>
</tr>
</tbody>
</table>

ART indicates antiretroviral therapy; BP, blood pressure; BMI, body mass index; CVD, cardiovascular disease; ESPRIT, Evaluation of Subcutaneous Proleukin® in a Randomized International Trial; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; SILCAAT, Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4⁺ Counts under Active Antiretroviral Therapy; SMART, Strategies for Management of Antiretroviral Therapy.
(IQR) levels of IL-6 for smokers and nonsmokers were 1.98 (1.19 to 3.23) and 1.65 (1.05 to 2.86), respectively (P < 0.001 for difference). To investigate whether the adjustment for smoking led to the lower OR for SMART, we compared unadjusted and smoking adjusted ORs for SMART participants. In the unadjusted model, the OR associated with a doubling of IL-6 was 1.29 (95% CI, 0.93 to 1.80); in the model adjusting for smoking, the OR was 1.30 (95% CI, 0.93 to 1.81).

There were 134 patients in the control arms of the 3 studies that experienced a CVD event (32 fatal and 102 nonfatal). ORs were similar to those cited for all patients in Table 3, but CIs were wider as a result of the smaller number of events. Adjusted ORs (fatal/nonfatal events) were 1.62 (95% CI, 0.96 to 2.74), 1.40 (95% CI, 0.88 to 2.25), 1.11 (95% CI, 0.82 to 1.51), and 1.89 (95% CI, 1.05 to 3.41) for IL-6, D-dimer, hsCRP, and the IL-6 and D-dimer score, respectively. Interaction P values for treatment/control and each biomarker were all >0.59.

### Biomarker Association With Mortality After a Nonfatal CVD Event

Among the 214 patients who had a nonfatal CVD event, there were 23 deaths (10.7%). Cumulative mortality 6 and 12 months after the nonfatal event for these patients, all of whom survived at least 28 days, was 2.9% and 4.0%, respectively.

In univariate analyses, higher levels of each of the biomarkers were associated with an increased risk of death (Table 4). HRs were reduced with covariate adjustment, yet remained significant for all 4 biomarkers. There was no evidence that the proportional hazards assumption did not hold for each biomarker (interaction P values all >0.73).

### Discussion

Based on our previous work and studies in the general population, we formulated 2 related hypotheses on the association of inflammatory and coagulation markers and the severity of future CVD events in HIV-positive patients. In analyses that adjusted for HIV- and CVD-related factors, we found that among HIV-positive patients who developed CVD: (1) those with higher levels of IL-6, D-dimer, and an IL-6 and D-dimer score, but not hsCRP, measured several years earlier were significantly more likely to have a fatal CVD event and (2) the risk of death after an MI, stroke, or CAD event was significantly increased among HIV-positive patients with higher baseline levels of IL-6, hsCRP, and an IL-6 and D-dimer score, but not D-dimer. In this latter analysis, the biomarkers

---

**Table 3.** Unadjusted and Covariate Adjusted* Odds Ratios for Fatal CVD † (Versus Nonfatal CVD ‡) According to Tertile and Associated With a Doubling of Each Biomarker or 1-Unit Increase of IL-6 and D-Dimer Score

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Lowest Tertile</th>
<th>Middle Tertile</th>
<th>Highest Tertile</th>
<th>OR Associated With Doubling of Biomarker</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>P Value</td>
<td>OR</td>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td>1.0</td>
<td>(0.66 to 2.64)</td>
<td>0.44</td>
<td>2.46</td>
</tr>
<tr>
<td>Adjusted</td>
<td>1.0</td>
<td>(0.69 to 2.88)</td>
<td>0.34</td>
<td>2.62</td>
</tr>
<tr>
<td>D-dimer (µg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td>1.0</td>
<td>(0.80 to 3.33)</td>
<td>0.18</td>
<td>2.47</td>
</tr>
<tr>
<td>Adjusted</td>
<td>1.0</td>
<td>(0.80 to 3.75)</td>
<td>0.16</td>
<td>2.70</td>
</tr>
<tr>
<td>hsCRP (µg/mL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td>1.0</td>
<td>(0.60 to 2.29)</td>
<td>0.65</td>
<td>1.49</td>
</tr>
<tr>
<td>Adjusted</td>
<td>1.0</td>
<td>(0.59 to 2.33)</td>
<td>0.65</td>
<td>1.55</td>
</tr>
<tr>
<td>IL-6 and D-dimer score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Univariate</td>
<td>1.0</td>
<td>(0.56 to 2.38)</td>
<td>0.71</td>
<td>3.07</td>
</tr>
<tr>
<td>Adjusted</td>
<td>1.0</td>
<td>(0.57 to 2.54)</td>
<td>0.64</td>
<td>3.67</td>
</tr>
</tbody>
</table>

hsCRP indicates high-sensitivity C-reactive protein; OR, odds ratio.

*Covariates include: study indicators, log-transformed time to event, age, gender, race, body mass index, HIV-RNA, baseline CD4+ cell count, and earlier AIDS at baseline.

†Number of fatal CVD events=74.

‡Number of nonfatal CVD events=214.

§Based on 2 df chi-square test.
Table 4. Unadjusted and Covariate Adjusted* Hazard Ratios for All-Cause Mortality After Nonfatal CVD† (n=214) Events Associated With a Doubling of Biomarker or 1-Unit Increase in IL-6/D-Dimer Score

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Median (IQR)</th>
<th>Univariate</th>
<th>Adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Deaths (n=23)</td>
<td>Survivors (n=191)</td>
<td>HR</td>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td>3.1 (2.3 to 6.2)</td>
<td>2.2 (1.5 to 3.2)</td>
<td>1.72</td>
</tr>
<tr>
<td>D-dimer, µg/mL</td>
<td>0.47 (0.29 to 0.59)</td>
<td>0.27 (0.17 to 0.42)</td>
<td>1.73</td>
</tr>
<tr>
<td>hsCRP, µg/mL</td>
<td>5.3 (2.6 to 7.5)</td>
<td>2.0 (1.0 to 4.9)</td>
<td>1.44</td>
</tr>
<tr>
<td>IL-6 and D-dimer score</td>
<td>0.94 (0.37 to 1.57)</td>
<td>0.18 (&lt;0.25 to 0.72)</td>
<td>1.88</td>
</tr>
</tbody>
</table>

CVD indicates cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; HR, hazard ratio.
* Covariates include: study indicators, log-transformed time to event, age, gender, race, body mass index, HIV-RNA at baseline and proximal to nonfatal CVD event, CD4+ cell count at baseline and proximal to nonfatal CVD event, and earlier AIDS at baseline.
† Number of deaths after a nonfatal CVD event—23, including deaths attributed to CVD and unwitnessed deaths not resulting from violence, suicide, or drug abuse.

were measured a median of 2.6 years before the nonfatal event. To our knowledge, the prognostic importance of these markers for fatal, as compared to nonfatal, CVD events has not been studied in the setting of HIV infection.

Considering the results based on the first hypothesis, our findings are consistent with studies in the general population that show an increased risk of more fatal CVD events for patients with higher inflammatory markers. In MRfit, higher CRP levels at baseline were significantly associated with CHD death, all of which occurred 11 to 17 years after the CRP measurement (P<0.001). No association (P=0.78) was found between baseline CRP and nonfatal MIs, which occurred 6 to 7 years after CRP measurement. In the PROSPER study, IL-6 and CRP, measured at baseline in over 5000 patients, were both more strongly related to fatal CVD events than nonfatal CVD events. Engström et al. measured 5 other inflammation-sensitive plasma proteins (ISPs)—fibrinogen, orosomucoid, α1-antitrypsin, haptoglobin, and ceruloplasmin—6075 healthy men and found that, for men who subsequently developed a coronary event, fatal events were related to the number of ISPs measured at the baseline examination, which was an average of 12.9 years before the events.

In addition to IL-6, D-dimer, a fibrin degradation product and marker of ongoing coagulation, was significantly associated with severity of CVD disease. We have previously shown that D-dimer is elevated among patients with HIV infection. The significant association of baseline D-dimer with severity of CVD outcomes may reflect activation of coagulation systems in response to low-grade inflammation associated with HIV infection. It has been shown that HIV replication alters the composition of extrinsic pathway coagulation factors, and this cycle of inflammation and coagulation resulting from infection may increase the risk of progressive organ dysfunction and death.

Higher levels of inflammatory markers and D-dimer for those with fatal CVD may also reflect greater underlying disease. In cross-sectional studies, higher D-dimer levels have been associated with severity of peripheral atherosclerosis.

In an overview of 3 studies, higher levels of IL-6 measured at the time of stroke diagnosis were associated with an increased risk of a poor outcome, including death, and concluded that IL-6 may be a general marker of disease severity. Although we excluded HIV-positive patients with a history of CVD, recent cross-sectional comparisons of HIV-positive men and women without a history of CVD with HIV-negative controls have found differences in vascular abnormalities. In 2 studies by the same group, those with HIV were found to have more noncalcified coronary plaque by CT angiography. Furthermore, in one of these studies, correlations between soluble CD163 and increased amount of noncalcified plaque suggests that monocyte and macrophage activation may contribute to formation of vulnerable plaque in HIV-positive patients. Thus, it is possible that those with higher inflammatory markers had more vulnerable plaque than those who did not. In another study, HIV-positive patients without a history of CVD had more structural and functional abnormalities based on cardiac MRI than HIV-negative patients.

Studies in the general population have reported that higher levels of markers of inflammation measured at the time of an acute coronary event are related to subsequent mortality, but not to recurrent coronary events. These observations may be related to the findings of our second hypothesis, that mortality after nonfatal CVD events would be higher among HIV-positive patients with higher, as compared to lower, levels of IL-6, hsCRP, and D-dimer. For patients in the general population, De Servi et al. speculated that the highest inflammatory markers observed during an acute coronary syndrome are more likely to be observed among patients who had high levels before the event. If HIV patients who are already in a state of ongoing immune activation with chronic low-grade inflammation are at increased risk of an exaggerated inflammatory response after their CVD event, as has been suggested based on findings in the general population, this could explain the findings based on our second hypothesis. However, we cannot directly address this because...
Severity of Cardiovascular Disease

Nordell et al

biomarkers were not measured at the time of the nonfatal CVD event. There are several limitations to our findings. Cause of death was uncertain for many of the deaths. However, because sudden cardiac deaths account for most cardiac and many non-AIDS deaths among HIV-positive individuals, we found it reasonable to consider unwitnessed deaths not attributable to suicide, drug abuse, or violence as fatal CVD. In addition, we showed, in a sensitivity analysis, that results did not differ when unwitnessed deaths were excluded from the logistic models. Another limitation was that important CVD risk factors at baseline were not fully assessed and could only be partially adjusted for. ORs were reduced when only SMART patients for whom smoking and blood lipids were measured at baseline were considered. Although IL-6 levels were higher among smokers than nonsmokers in SMART, the percentages of patients with fatal and nonfatal events who smoked were similar (Table 2), and ORs from unadjusted and smoking-adjusted models were also similar, suggesting that smoking was not an important confounding factor in studying severity of CVD events. We also did not measure the biomarkers in the time period immediately before events occurred or at the time of the event. Correlations among measurements taken more remotely with those proximal to the event may be informative. Finally, power for both hypotheses was limited, particularly for the analyses restricted to the subgroup of patients who participated in SMART, as well as for the patients in the control arms of the 3 studies, and, as a consequence, CIs are wide for those analyses. Strengths include the central measurement of the biomarkers, excellent follow-up, and the uniqueness of this investigation in HIV-positive patients.

Conclusion

In conclusion, we sought to assess the prognostic value of inflammatory and coagulation markers for fatal outcomes among patients with HIV who experience CVD events. We found that activated inflammatory and coagulation pathways, as demonstrated by higher IL-6 and D-dimer plasma levels, are associated with a greater risk of fatal, as compared to nonfatal, CVD and a greater risk of death after a nonfatal CVD event. These findings suggest that chronic inflammation and activated coagulation associated with HIV leads to a poor outcome when a CVD event occurs.

Acknowledgments

The authors acknowledge the SMART, ESPRIT, and SILCAAT patients. See N Engl J Med 2006;355:2283-2296 for the complete list of SMART investigators and N Engl J Med 2009;361:1548-1559 for the complete list of ESPRIT and SILCAAT investigators.

Sources of Funding

This study was funded by the National Institutes of Health (Grant No.: U01AI46957 and U01AI068641 [ESPRIT and SMART]; U01AI042170 and U01AI46362 [SMART]). SILCAAT was supported by grants from Chiron and Novartis. The funding sources had no role in data collection, data analysis, or decisions to publish the results.

Disclosures

None.

References

Severity of Cardiovascular Disease  Nordell et al


**SUPPLEMENTAL MATERIAL**

Supplemental Table 1: Summary of biomarker measurements made on 20 samples

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>U. of Vermont [mean (IQR)]</th>
<th>SAIC-Frederick [mean (IQR)]</th>
<th>Correlation</th>
<th>Average Difference* (U. of Vermont–SAIC-Frederick) (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6 (pg/ml)</td>
<td>2.63 (1.78–3.75)</td>
<td>2.30 (1.50–3.18)</td>
<td>0.91</td>
<td>0.12 (0.38)</td>
</tr>
<tr>
<td>D-dimer (µg/ml)</td>
<td>0.29 (0.13–0.59)</td>
<td>0.41 (0.21–0.82)</td>
<td>0.81</td>
<td>-0.44 (0.96)</td>
</tr>
<tr>
<td>hsCRP(µg/ml)</td>
<td>2.39 (0.91–5.81)</td>
<td>2.18 (0.87–6.28)</td>
<td>0.99</td>
<td>0.15 (0.27)</td>
</tr>
</tbody>
</table>

* After log-transformation
SMART Study Group (see also N Eng J Med 2006; 355:2283-2296)

Community Programs for Clinical Research on AIDS Chair’s Office and Operations Center:
F. Gordin (group leader), E. Finley, D. Dietz, C. Chesson, M. Vjecha, B. Standridge, B. Schmetter, L. Grue, M. Willoughby, A. Demers;

Regional Coordinating Centers
Copenhagen:
London:
Sydney:

Statistical and Data Management Center
Minneapolis:

Electrocardiography Reading Center:
R. Prineas, C. Campbell;
End Point Review Committee:
NIAID Data and Safety Monitoring Board:
NIAID
K. Klingman, S. Lehrman;

SMART Clinical Site Investigators
Argentina:
Australia:
Austria:
A. Rieger, V. Tozeau, A. Aichelburg, N. Vetter;
Belgium:
N. Clumeck, S. Dewit, A. de Roo, K. Kabeya, P. Leonard, L. Lynen, M. Moutschen, E. O’Doherty;
Brazil:
Canada:
Chile:
M.J. Wolff Reyes, R. Northland;

**Denmark:**  

**Estonia:**  
M. Raukas, K. Zilmer;

**Finland:**  
J. Justinen, M. Ristola;

**France:**  

**Germany:**  

**Greece:**  

**Ireland:**  
C.J. Bergin, B. Mooka;

**Israel:**  

**Italy:**  

**Japan:**  
M. Honda, M. Ishisaka;

**Lithuania:**  
S. Caplinskias, V. Uzdaviniene;

**Luxembourg:**  
J.C. Schmit, T. Staub;

**Morocco:**  
H. Himmich, K. Marhoum El Filali;

**New Zealand:**  
G.D. Mills, T. Blackmore, J.A. Masters, J. Morgan, A. Pithie;

**Norway:**  
J. Brunn, V. Ormассsen;

**Peru:**  
A. La Rosa, O. Guerra, M. Espichan, L. Gutierrez, F. Mendo, R. Salazar;

**Poland:**  
B. Knytz, A. Horban, E. Bakowska, M. Beniowski, J. Gasiorowski, J. Kwiatkowski;

**Portugal:**  
F. Antunes, R.S. Castro, M. Doroana, A. Horta, K. Mansinho, A.C. Miranda, I.V. Pinto, E. Valadas, J. Vera;

**Russia:**  
A. Rakhmanova, E. Vinogradova, A. Yakovlev, N. Zakharova;

**South Africa:**  
R. Wood, C. Orrel;
Spain:

Switzerland:

Thailand:
P. Phanuphak, K. Ruxrungtham, W. Pumpradit, P. Chetschotisakd, S. Danthongdee, S. Kiertiburanakul, V. Klinbuayaem, P. Mootsikapun, S. Nonenoy, B. Piyavong, W. Prasithsirikul, P. Raksaulkarn;

United Kingdom:

Uruguay:
E. Savio, M. Vacarezza.
ESPRIT and SILCAAT Study Groups (see also N Eng J Med 2009; 361: 1548-1559)

Coordinating Centers:

Copenhagen:

London:
B Angus, A Babiker, B Cordwell, J Darbyshire, W Dodds, S Fleck, J Horton, F Hudson, Y Moraes, F Pacciarini, A Palfreeman, N Paton, N Smith, F van Hooff.

Minneapolis:
J Bebchuk, G Collins, E Denning, A DuChene, L Fosdick, M Harrison, K Herman-Lamin, E Krum, G Larson, J Neaton, R Nelson, K Quan, S Quan, T Schultz, G Thompson, D Wentworth, N Wyman.

Sydney:
C Carey, F Chan, D Cooper, B Cordwell, D Courtney-Rodgers, F Drummond, S Emery, M Harrod, S Jacoby, L Kearney, M Law, E Lin, S Pett, R Robson, N Seneviratne, M Stewart, E Watts.

Washington:
E Finley, F Gordin, A Sánchez, B Standridge, M Vjeka.

Endpoint Review Committee:

Data and Safety Monitoring Board:

National Institute of Allergy and Infectious Disease:

International Drug Distribution (CTS Inc., Durham, North Carolina):
V Costas, J Eckstrand.

Specimen Repository (SAIC Frederick, Inc.):
S Brown.

Clinical Sites for ESPRIT and/or SILCAAT:

Argentina:

Australia:

Austria:
A Aichelburg, P Cichon, B Gemeinhart, A Rieger, B Schmied, V Touzeau-Romer, N Vetter.

Belgium:
R Colebunders, N Clumeck, A DeRoo, K Kabeya, E O'Doherty, S de Wit.

Brazil:

**Canada (CTN):**

**Denmark:**

**France (ANRS):**

**Germany:**

**Ireland:**
F Mulcahy, DI Reidy.

**Israel:**

**Italy:**

**Japan:**
A Iwamoto, Y Kikuchi, N Miyazaki, M Mori, T Nakamura, T Odawara, S Oka, T Shirasaka, M Tabata, M Takano, C Ueta, D Watanabe, Y Yamamoto.

**Morocco:**
I Erradey, H Himmich, K Haroum El Filali.

**The Netherlands:**

**Norway:**
J Bruun, D Kvale, A Maeland.

**Poland:**
Portugal:

Singapore:
E Chia, E Foo, F Karim, PL Lim, A Panchalingam, N Paton, A Quek.

Spain:

Sweden:
G Bratt, A Hollander, P Olov Pehrson, I Petz, E Sandstrom, A Sönnerborg.

Switzerland:
E Bernasconi, V Gurtner.

Thailand:

United Kingdom:

United States: